PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.44%
Revenue growth similar to 3141.T's 6.56%. Walter Schloss would see if both companies share industry tailwinds.
10.34%
Gross profit growth above 1.5x 3141.T's 4.29%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
32.32%
EBIT growth 75-90% of 3141.T's 38.00%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
35.65%
Operating income growth above 1.5x 3141.T's 2.02%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
36.95%
Net income growth at 50-75% of 3141.T's 53.84%. Martin Whitman would question fundamental disadvantages in expenses or demand.
-31.52%
Negative EPS growth while 3141.T is at 51.73%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-31.52%
Negative diluted EPS growth while 3141.T is at 51.73%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
100.00%
Share change of 100.00% while 3141.T is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
100.00%
Diluted share count expanding well above 3141.T's 1.39%. Michael Burry would fear significant dilution to existing owners' stakes.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.06%
Negative 10Y revenue/share CAGR while 3141.T stands at 33.58%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-9.06%
Negative 5Y CAGR while 3141.T stands at 33.58%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-21.15%
Negative 3Y CAGR while 3141.T stands at 37.39%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-100.00%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-100.00%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
15.25%
Below 50% of 3141.T's 221.75%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
15.25%
Below 50% of 3141.T's 221.75%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
6.59%
Below 50% of 3141.T's 215.55%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.61%
Negative 3Y equity/share growth while 3141.T is at 49.10%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-100.00%
Cut dividends over 10 years while 3141.T stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-100.00%
Negative 5Y dividend/share CAGR while 3141.T stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-99.47%
Firm’s AR is declining while 3141.T shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.66%
Inventory is declining while 3141.T stands at 12.88%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.83%
Asset growth well under 50% of 3141.T's 4.98%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-47.19%
We have a declining book value while 3141.T shows 5.01%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-76.30%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
52.94%
SG&A growth of 52.94% while 3141.T is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.